With this high-level training you will acquire the necessary skills to perform early detection, more efficient surgery and more precise treatment of patients with digestive oncologic pathologies"

Digestive tumors represent an important cause of morbidity and mortality in the population of both sexes. It is estimated that of the new cases of cancer detected each year, 26% are digestive tumors. The incidence of these has varied over the years. While that of stomach cancer has been decreasing, that of colon tumor has been increasing and is crowned as the digestive cancer with the highest incidence.

The continuous improvement and sophistication of imaging methods, the refinement of some surgical techniques, the increased hierarchization of certain pathological findings, the inclusion of molecular biology in clinical practice, the incorporation of personalized medicine, changes in many classical therapeutic approaches, technological advances for the administration of radiotherapy, the incorporation of immunotherapy and new combined modalities, new complications and sequelae of new treatments, are some of the factors that make the care of patients with digestive tumors an increasingly complex activity.

In order to respond to these new complexities and new demands, the Hybrid professional master’s degree in Digestive Oncology has been designed, with the participation of a group of excellent professionals who will make an innovative proposal aimed at improving and strengthening students' skills, helping personalized learning and creating a new generation of specialists in Digestive Oncology.

To this end, the program has been oriented to the knowledge of new standards, the acquisition of experience for a multidisciplinary vision, the contact with new treatments and the ability to recognize the cases in which it is necessary to cooperate with more complex health care centers.

Likewise, this program will allow you to develop, in real patients and in a hospital setting with state-of-the-art resources, your maximum potential and growth in the area of Digestive Oncology. You will approach patients with digestive pathologies using the latest techniques based on scientific evidence, and achieving results previously difficult to achieve.

Specialize in Digestive Oncology and stand out professionally in a booming sector"

This Hybrid professional master’s degree in Digestive Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Development of more than 100 clinical cases presented by experts in Digestive Oncology
• The graphic, schematic, and practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Diagnostic-therapeutic developments in the assessment, diagnosis, and intervention in Digestive System Oncology
• It contains practical exercises where the self-assessment process can be carried out to improve learning
• Iconography of clinical and diagnostic imaging tests
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• With special emphasis on evidence-based medicine and research methodologies in Digestive System Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection
• In addition, you will be able to carry out a clinical internship in one of the best hospitals in the world

You are just a click away from adding to your studies the possibility of a clinical internship with the highest standards of quality and technological level in an elite hospital center"

In this Professional Master's Degree proposal, of a professionalizing nature and blended learning modality, the program is intended to update nursing professionals who develop their functions in high performance centers, clinical or hospital centers, and who require a high level of qualification. The content is based on the latest scientific evidence and is organized in a didactic way to integrate theoretical knowledge into nursing practice. The theoretical-practical elements allow professionals to update their knowledge and help them to make the right decisions in patient care. The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive education program to learn in real situations.

This program's design is based on Problem Based Learning, by means of which the student must try to solve different professional practice situations that will be presented throughout the program. For this purpose, the student will be assisted by an innovative interactive video system created by renowned experts.

Take advantage of the opportunity to take an intensive 3-week program in a prestigious hospital center and acquire all the knowledge you need to grow personally and professionally"

Update your knowledge through the Hybrid professional master’s degree in Digestive Oncology, in a practical way and adapted to your needs"

This avant-garde program has been created under the combination of the Relearning method, for the development of the syllabus and the design of the study material, to be consulted 100% online. And a 3-week internship in a prestigious center that you will complete once you complete this academic itinerary of 7 extended modules. Thanks to the innovative design, the specialist will be able to combine and organize their current agenda according to their convenience and most up-to-date work approach.

TECH combines 100% online theory with practical on-site study in this program"

Module 1.  Molecular biology and translational oncology

1.1. Molecular Mechanisms of Cancer
1.2. Tumor Immunology: Basis of Cancer Immunotherapy
1.3. Role of the Biobank in Clinical Research
1.4. Understanding the New Technology: Next Generation Sequence (NGS) in clinical practice
1.5. Liquid Biopsies: Fashion or Future?
1.6. Update on Molecular Markers for Treatment Decisions in Gastrointestinal Malignancies
1.7. Do Molecular and Immunological Classifications Have Clinical Implications Today?

Module 2. Upper Gastrointestinal Tract Tumors

2.1. Oesophageal Cancer

2.1.1. Differences between Squamous Carcinoma and Esophagus Adenocarcinoma
2.1.2. Endoscopic Aspects of Esophageal Cancer: Diagnosis and Staging
2.1.3. Clinical Impact of 18F-FDG PET/CT in the Therapeutic Management of Patients with Esophageal Cancer
2.1.4. Endoscopic Treatment of Superficial Esophageal Neoplasms
2.1.5. Conventional Surgical Approach to Esophageal Carcinoma
2.1.6. Minimally Invasive and Robotic Surgery of Esophageal Cancer
2.1.7. Evolution in Neoadjuvant and Adjuvant Treatment of Esophageal Cancer
2.1.8. Management of Metastatic Esophageal Cancer

2.2. Gastric Cancer

2.2.1. Diagnosis and Staging of Gastric Adenocarcinoma
2.2.2. Minimally Invasive and Robotic Surgery of Gastric Cancer
2.2.3. Lymphadenectomy Extension in Gastric Cancer
2.2.4. Neoadjuvant and Adjuvant Treatment in Gastric Cancer: What Is the Optimal Approach?
2.2.5. National Registry of Advanced Gastric Cancer (AGAMENON)
2.2.6. First-Line Treatment of HER2-Negative Metastatic Gastric Cancer
2.2.7. Second-Line Treatment of HER2-Negative Metastatic Gastric Cancer
2.2.8. Metastatic Gastric Cancer: Impact of Drugs Targeting the HER2 Pathway
2.2.9. Metastatic Gastric Cancer: Impact of Immune Checkpoint Inhibitors

Module 3. Lower Gastrointestinal Tract Tumors

3.1. Colon and Rectum Cancer

3.1.1. Colorectal Cancer: Epidemiology, Etiology and Incidence
3.1.2. Molecular Mechanisms Involved in the Invasion and Metastasis Process in Digestive Tumors
3.1.3. Molecular Classification of Colon Cancer: New insights
3.1.4. Biomarkers in Colorectal Cancer
3.1.5. Early Detection Program for Colon and Rectum Cancer
3.1.6. Familial forms of colorectal cancer (polyposis-associated and nonpolyposis-associated)
3.1.7. Cancer associated with chronic Inflammatory Bowel Diseases and the treatments received
3.1.8. Diagnosis and Endoscopic Management of Polyps and Advanced Lesions
3.1.9. Clinical Impact of FDG-PET/CT in the Staging of Colorectal Cancer
3.1.10. Role of Endoscopic Utrasonography (EUS) and Magnetic Resonance Imaging in the staging of rectal cancer
3.1.11. Laparoscopic vs. robotic colon cancer surgery
3.1.12. Surgical Management of Familial Non-Polyposis Colon Cancer
3.1.13. Surgery for Familial Adenomatous Polyposis
3.1.14. Current Adjuvant Treatment of Colon Cancer and Proposals for the Future in the Adjuvant Treatment of Colon Cancer
3.1.15. Total Mesorectal Excision: Open, Laparoscopic and Robotic
3.1.16. Transanal Approach to Rectal Tumors
3.1.17. Neoadjuvant Treatment in Rectal Cancer
3.1.18. Postoperative Treatment after Neoadjuvant and Radical Surgery
3.1.19. Observe and Wait for Low Rectal Cancers after Neoadjuvant Therapy with Complete Clinical Response
3.1.20. Invasive pelvic tumors: pelvic exenteration
3.1.21. Therapeutic Advances in Colon and Rectal Cancer: Improving Patient Survival Day by Day
3.1.22. What Is the Best Treatment Option After Second Line Therapy in Advanced Colorectal Cancer?
3.1.23. Acquired Resistance to EGFR Antibodies: How to Manage
3.1.24. Immunotherapy in Metastatic Colorectal Cancer
3.1.25. Rectal Cancer with Synchronous and Resectable Liver Metastases
3.1.26. Management of Colorectal Cancer Liver Metastases
3.1.27. Total excision of the mesocolon: when, how, why
3.1.28. Role of Endoscopy in the Management of Advanced Colorectal Cancer

Module 4. Other Digestive Tract Tumors

4.1. Appendicular Tumors

4.1.1. Appendicular Tumors: Surgical Implications

4.2. Peritoneal Carcinomatosis

4.2.1. Peritoneal Carcinomatosis: Surgical Treatment and Postoperative Intraperitoneal Chemotherapy

4.3. Anal Cancer

4.3.1. Treatment of Localized Anal Cancer
4.3.2. Treatment of Locally Advanced Cancer
4.3.3. Treatment of Radiation Therapy in Colon Cancer
4.3.4. Treatment of Metastatic Anal Cancer

4.4. Neuroendocrine Tumors

4.4.1. Neuroendocrine Tumors of the Small Intestine
4.4.2. Neuroendocrine Tumors of the Pancreas
4.4.3. Surgical Treatment of Non-Functioning Neuroendocrine Pancreas Tumors
4.4.4. Surgical Treatment of Gastrinoma
4.4.5. Surgical Treatment of Insulinoma
4.4.6. Pancreas Endocrine Tumors Surgery: Glucagonoma, Vipoma
4.4.7. Overview of Systemic Treatment of Metastatic Neuroendocrine Tumors in the Pancreatic Gastroenteropancreatic Tract

4.5. GIST

4.5.1. Biology, Diagnosis and Management of Gastrointestinal Stromal Tumors (GIST)
4.5.2. The Role of 18F-FDG PET/CT in GI Stromal Tumors
4.5.3. Surgical Treatment of Gastrointestinal Stromal Tumors (GIST)
4.5.4. GIST as a Model of Translational Research: 15 Years of Experience
4.6. Lymphomas
4.6.1. Gastric MALT Lymphoma
4.6.2. Lymphomas in Other Digestive Regions

Module 5. Pancreatic Cancer, Biliary Tract Tumors and Hepatocarcinoma

5.1. Pancreatic Cancer

5.1.1. Epidemiology, Risk Factors and Diagnosis of Pancreatic Cancer
5.1.2. Use of Endoscopic Retrograde Cholangiopancreatography (ERCP) in Patients with Pancreatic Masses and Biliary Tract Obstruction
5.1.3. Use of Endoscopic Ultrasonography (EUS) in Pancreatic Cancer Patients or Pancreatic Masses
5.1.4. Endosonographic Cholangiopancreatography (CEPEUS) in Pancreatic Masses and Biliary Tract Obstruction
5.1.5. Diagnostic Modalities for Defining Pancreatic Cancer Resectability (CT, EUS, MRI)
5.1.6. Clinical Impact of PET/CT with 18F-FDG in the Therapeutic Management of Patients with Pancreas Cancer
5.1.7. Borderline Resectable Pancreatic Cancer
5.1.8. Laparoscopic Distal Pancreatectomy: Indications and Technique
5.1.9. Cephalic pylorus-sparing duodenopancreatectomy versus Whipple in pancreatic cancer
5.1.10. Surgical Treatment of Ampulomas
5.1.11. Adjuvant and Neoadjuvant Chemotherapy Treatment for Pancreatic Cancer
5.1.12. Adjuvant and Neoadjuvant Radiotherapy Treatment for Pancreatic Cancer
5.1.13. Advances in the Treatment of Patients with Metastatic Pancreatic Cancer
5.1.14. Screening for Familial and Hereditary Pancreatic Cancer
5.1.15. Cystic Lesions of the Pancreas of Neoplastic Origin
5.1.16. Surgery for Cystic Tumors of the Pancreas

5.2. Cholangiocarcinoma and Gallbladder Cancer

5.2.1. Epidemiology, Risk Factors and Diagnosis of Cholangiocarcinoma and Gallbladder Cancer
5.2.2. What to Do with Cholangiocarcinoma
5.2.3. Advances in the Treatment of Patients with Metastatic Cholangiocarcinoma and Gallbladder Cancer

5.3. Hepatocellular Carcinoma

5.3.1. Epidemiology, Risk Factors and Diagnoses for Hepatocellular Carcinoma
5.3.2. Staging and Treatment of Hepatocellular Carcinoma
5.3.3. Resective Treatment vs. Liver Transplantation in Hepatocellular Carcinoma
5.3.4. Locally advanced disease with vascular involvement: local versus systemic therapy?
5.3.5. Drainage of Malignant Biliary Obstruction by Interventional Radiology
5.3.6. First and Second Line of Systemic Therapy in Hepatocellular Carcinoma
5.3.7. Recurrence of Hepatocellular Carcinoma after Transplantation

Module 6. Collaboration in the Management of Oncology Patients

6.1. Palliative Management

6.1.1. The Palliative Care Consultant in the Multidisciplinary Team: Treatment planning
6.1.2. A Model of Integration with Oncology: Enhanced Supportive Care
6.1.3. Informed Consent: Are We Really Informing Our Patients?
6.1.4. Palliative Management of Symptoms in Gastrointestinal Tumors
6.1.5. Palliative Endoscopic Treatments
6.1.6. Palliative Surgical Treatment

6.2. Emergencies and Comorbidities

6.2.1. Why do Patients with Gastrointestinal Tumors Attend the Emergency Department and How Can Outcomes Be Improved?
6.2.2. Management of Infectious Comorbidities
6.2.3. Management of Cardiovascular Comorbidities
6.2.4. Neurologic Comorbidity Management
6.2.5. Management of Endocrinological Comorbidities
6.2.6. Management of Nutritional Comorbidities
6.2.7. Gastrointestinal Tumors in the Elderly
6.2.8. Outpatient Care of Patients with Digestive System Oncology Pathology

Module 7. From Clinical Management to Networking

7.1. Clinical Management in Digestive Tumor Units

7.1.1. Basis of Clinical Management
7.1.2. Intensified Recovery Programs in Colon Surgery
7.1.3. Members, Functions and Decision-Making in Multidisciplinary Teams

7.2. Improving Networking

7.2.1. Technological Platforms for Patient Monitoring and Control
7.2.2. The Collaborative On-line World
7.2.3. Decision Support Systems in Oncology Based on Artificial Intelligen

With the ease of choosing your study space both theoretically and practically. TECH offers freedom, flexibility and quality in this program"